PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.43%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
12.93%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
5.37%
Other expenses growth 0-10% reflects moderate increase. Benjamin Graham would investigate nature of expenses.
14.34%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
14.34%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
5.37%
D&A growth 5-10% suggests significant asset additions. Howard Marks would investigate investment returns.
-16.61%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-14.34%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-295.23%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-20.40%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-19.61%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-20.61%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
0.76%
Share increase 0-2% indicates slight dilution. Howard Marks would investigate necessity.
No Data
No Data available this quarter, please select a different quarter.